Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 5/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292893 | 0.84 | TNF (0.50) | TNFMGLLGRM5OPRM1OPRK1 | |
| SCHEMBL2294348 | 0.81 | TNF (0.47) | TNFMGLLPDCD1CD274KMT2A | |
| SCHEMBL6689096 | 0.78 | TNF (0.80) | TNF | |
| SCHEMBL10695287 | 0.76 | TNF (0.39) | TNFMEN1KMT2A | |
| SCHEMBL5099707 | 0.76 | GRM4 (0.45) | TNFMGLLGRM4ADRA1DADRA1A | |
| SCHEMBL10683382 | 0.75 | KMT2A (0.44) | TNFGRM4SLC6A2SLC6A4MEN1 | |
| SCHEMBL10684402 | 0.75 | KMT2A (0.44) | TNFGRM4SLC6A2SLC6A4MEN1 | |
| SCHEMBL10695288 | 0.73 | TNF (0.39) | TNFKMT2A | |
| SCHEMBL5089141 | 0.73 | FFAR1 (0.48) | TNFGRM4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5098915 | 0.72 | FFAR1 (0.47) | TNFGRM4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| EP-2164326-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | Euro-Celtique, S.A. (LU) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | CACNA1E, CACNA1B, CACNA1S | TNF 3052/4885MGLL 2636/4885GRM5 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.